doi: 10.3389/fonc.2012.00143.
eCollection 2012.
The confluence of radiotherapy and immunotherapy
Affiliations
- PMID: 23087904
- PMCID: PMC3472545
- DOI: 10.3389/fonc.2012.00143
Item in Clipboard
The confluence of radiotherapy and immunotherapy
Front Oncol.
.
Abstract
Radiotherapy (RT) has been considered a local modality and outcomes have emphasized local and regional control of tumors. Recent data suggests that RT may activate the immune system and the combination of radiation therapy and immune therapies may have the potential to improve both local and distant control of tumor deposits. Below we review principals underlying the concepts of combining both modalities.
Keywords: T cell; danger signal; immunotherapy; radiation; radiotherapy.
Similar articles
-
Radiotherapy and immunotherapy: a beneficial liaison?Nat Rev Clin Oncol. 2017 Jun;14(6):365-379. doi: 10.1038/nrclinonc.2016.211. Epub 2017 Jan 17. Nat Rev Clin Oncol. 2017. PMID: 28094262 Review.
-
Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy.Mol Ther. 2000 Sep;2(3):195-203. doi: 10.1006/mthe.2000.0114. Mol Ther. 2000. PMID: 10985949
-
Combinatorial strategies of radiotherapy and immunotherapy in nasopharyngeal carcinoma.Chin Clin Oncol. 2018 Apr;7(2):15. doi: 10.21037/cco.2018.04.05. Chin Clin Oncol. 2018. PMID: 29764160 Review.
-
Combining radiation plus immunotherapy to improve systemic immune response.J Thorac Dis. 2018 Feb;10(Suppl 3):S468-S479. doi: 10.21037/jtd.2018.01.130. J Thorac Dis. 2018. PMID: 29593892 Free PMC article. Review.
-
Systemic Immunostimulatory Effects of Radiation Therapy Improves the Outcomes of Patients With Advanced NSCLC Receiving Immunotherapy.Am J Clin Oncol. 2020 Mar;43(3):218-228. doi: 10.1097/COC.0000000000000651. Am J Clin Oncol. 2020. PMID: 31842114 Review.
Cited by
-
Radiotherapy effects on anti-tumor immunity: implications for cancer treatment.Front Oncol. 2013 May 22;3:128. doi: 10.3389/fonc.2013.00128. eCollection 2013. Front Oncol. 2013. PMID: 23734344 Free PMC article. No abstract available.
-
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.Front Oncol. 2015 Feb 16;5:34. doi: 10.3389/fonc.2015.00034. eCollection 2015. Front Oncol. 2015. PMID: 25763356 Free PMC article. Review.
-
High IL-1R8 expression in breast tumors promotes tumor growth and contributes to impaired antitumor immunity.Oncotarget. 2017 Jul 25;8(30):49470-49483. doi: 10.18632/oncotarget.17713. Oncotarget. 2017. PMID: 28533483 Free PMC article.
-
Cancer-associated fibroblasts from lung tumors maintain their immunosuppressive abilities after high-dose irradiation.Front Oncol. 2015 May 12;5:87. doi: 10.3389/fonc.2015.00087. eCollection 2015. Front Oncol. 2015. PMID: 26029659 Free PMC article.
-
Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy.Oncoimmunology. 2015 May 22;4(6):e1008842. doi: 10.1080/2162402X.2015.1008842. eCollection 2015 Jun. Oncoimmunology. 2015. PMID: 26155423 Free PMC article.
References
-
- Ahrens S., Zelenay S., Sancho D., Hanč P., Kjær S., Feest C., et al. (2012). F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity 36 635–645 - PubMed
-
- Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., et al. (2007). Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13 1050–1059 - PubMed
-
- Bianchi M. E. (2006). DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 81 1–5 - PubMed
-
- Bianchi M. E., Manfredi A. A. (2007). High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol. Rev. 220 35–46 - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
